BioForce Nanosciences Holdings, Inc. reported no revenue for the quarter ended March 31, 2026, continuing its pre-commercial stage operations. The company recorded a net loss of $102,411, a narrower loss than the prior-year quarter, driven partly by $15,322 of other income from a legal settlement.
Operating expenses were $117,733, mainly board compensation and general and administrative costs. At March 31, 2026, BioForce had $6,347 in cash, total liabilities of $727,301, and an accumulated deficit of $162,514,528, resulting in a stockholders’ deficit of $720,954.
Management discloses substantial doubt about the company’s ability to continue as a going concern and notes reliance on a one-time legal settlement and related-party support. After quarter-end, a lender converted a $10,000 loan into 24,250 restricted shares, and the controlling shareholder sold approximately 80% of the company’s stock in a private transaction.
BioForce Nanosciences Holdings, Inc. reports another year with no operating revenue in 2025 and a larger net loss of $1,291,951, compared with $490,437 in 2024. The loss mainly reflects a $802,000 loss on liability settlement tied to issuing shares for accrued compensation.
At December 31, 2025, the company held only $786 in cash against $619,329 in liabilities and an accumulated deficit of $162,412,117, leading auditors and management to highlight substantial doubt about its ability to continue as a going concern. To pay $2,173,000 of accrued pay and related-party fees, it issued 4,250,000 restricted shares, increasing outstanding common stock to 33,521,755.
The supplement business generated zero unit sales of its BioForce Eclipse product in both 2025 and 2024, while operations were funded largely through related-party loans. Management reports material weaknesses in internal control over financial reporting, and disclosure controls were deemed not effective as of year-end.
BioForce Nanosciences Holdings, Inc. (BFNH) reported a very small balance sheet at September 30, 2025, with $784 in cash and total assets and $500,722 in total liabilities, resulting in a stockholders’ deficit of $499,938. The company generated no revenue for the three- and nine-month periods ended September 30, 2025 or 2024, reflecting no unit sales of its BioForce Eclipse supplement.
For the nine months ended September 30, 2025, BioForce recorded a net loss of $1,173,346, compared with a loss of $367,277 a year earlier, driven largely by a $801,193 loss on liability settlement from issuing 4,250,000 shares to satisfy $2,173,000 of amounts owed to a director. The accumulated deficit reached $162,293,512, and the company discloses substantial doubt about its ability to continue as a going concern, relying on related-party loans, including a $10,000 cash infusion in November 2025, and acknowledging material weaknesses in internal control over financial reporting.